share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer WAGNER CHARLES F JR

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer WAGNER CHARLES F JR

福泰製藥 | 4：持股變動聲明-高管 WAGNER CHARLES F JR
美股sec公告 ·  05/31 04:11
牛牛AI助理已提取核心訊息
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,250 shares of common stock on May 28, 2024. The transaction was executed at a price of $454.79 per share, resulting in a total sale value of approximately $1.48 million. Following the sale, Wagner's direct holdings in the company amount to 50,387 shares. The sale took place through an open market transaction, indicating a standard practice of stock disposal by company insiders.
Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,250 shares of common stock on May 28, 2024. The transaction was executed at a price of $454.79 per share, resulting in a total sale value of approximately $1.48 million. Following the sale, Wagner's direct holdings in the company amount to 50,387 shares. The sale took place through an open market transaction, indicating a standard practice of stock disposal by company insiders.
Vertex Pharmicals Inc.（VRTX）執行副總裁兼首席財務官小查爾斯·瓦格納於2024年5月28日完成了3,250股普通股的出售。該交易以每股454.79美元的價格執行，總銷售價值約爲148萬美元。出售後，瓦格納在公司的直接持股量爲50,387股。此次出售是通過公開市場交易進行的，這表明了公司內部人士處置股票的標準做法。
Vertex Pharmicals Inc.（VRTX）執行副總裁兼首席財務官小查爾斯·瓦格納於2024年5月28日完成了3,250股普通股的出售。該交易以每股454.79美元的價格執行，總銷售價值約爲148萬美元。出售後，瓦格納在公司的直接持股量爲50,387股。此次出售是通過公開市場交易進行的，這表明了公司內部人士處置股票的標準做法。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。